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Uncoating of Human Immunodeficiency Virus type 1 (HIV-1) and type 2 (HIV-2) conical
cores is an important early step for establishment of infection. In Old World Monkey
(OWM) cells, the TRIM5α cellular factor potently suppresses an early step of infection by
HIV-1. Previously, biochemical studies using whole cell lysates of infected cells revealed
that OWM TRIM5α accelerates the uncoating of HIV-1, leading to premature reverse transcription. In the present study, we re-evaluated uncoating kinetics of HIV-1 in the presence
of OWM TRIM5α by using an in situ uncoating assay, which allowed us to differentiate productive HIV-1 entry from simple (non-productive) endocytosis. Results showed that the
uncoating kinetics of HIV-1 was indeed accelerated in the presence of OWM TRIM5α. Furthermore, we adapted an in situ uncoating assay to HIV-2, which showed wide variations in
TRIM5α sensitivity among different isolates. HIV-2 isolate GH123, whose infectivity was
suppressed by cynomolgus monkey (CM) TRIM5α, showed accelerated uncoating in the
presence of CM TRIM5α. In contrast, mutant HIV-2 ASA, whose infectivity was unaltered by
CM TRIM5α, showed no change in uncoating kinetics in the presence of CM TRIM5α.
These results confirmed and further extended the previous notion that accelerated uncoating is associated with restriction activity of TRIM5α against lentiviruses.
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Background
Uncoating of the lentivirus core, which is composed of *1,000 capsid proteins (CA), is an important process for establishment of viral infection. Human Immunodeficiency Virus (HIV)
infection begins with the binding of viral glycoprotein to the cellular receptor and co-receptors,
a step that is followed by fusion of the viral and cellular membranes. After the fusion, a conical
core that contains two viral genomic RNAs and several viral proteins is released into the cytoplasm of the target cell. In the cytoplasm, CAs eventually dissociate from the viral complex in a
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process termed uncoating. During the uncoating process, reverse transcription (RT) of the
viral genomes is initiated. The resulting double-stranded DNA is associated with viral and cellular proteins, forming a structure designated the pre-integration complex (PIC). The PIC migrates into the nucleus, where viral DNA integrates into the chromosomal DNA of the target
cell. Several studies have reported that mutations in the HIV type 1 (HIV-1) CA-encoding
gene affect viral core stability [1–4]. Changes in core stability caused by some of these CA mutations seem to affect uncoating kinetics, which may result in impaired RT or nuclear entry.
Thus, timely uncoating is thought to be important for efficient HIV-1 infection.
To analyze uncoating kinetics of HIV-1 in infected cells, Campbell et al. developed an in
situ uncoating assay [5] by using fluorescently labeled HIV-1. In that assay, HIV-1 was doublelabeled using a green fluorescent protein (GFP) fused with viral protein Vpr (GFP-Vpr) along
with a protein consisting of the amino-terminal 15 amino acids of the Src protein (S15) fused
with a red fluorescent protein (RFP). S15 contains a signal peptide for membrane trafficking of
Src, and therefore directs the fused RFP to the plasma membrane and viral envelope. The RFP
signals in HIV-1 were observed to disappear after productive entry of the virus into the host
cell. The infected cells then were fixed and stained with a Cy5-labeled antibody detecting HIV1 p24 CA; the fluorescent signal was analyzed using fluorescence microscopy. The total complexes that entered the cytoplasm (green spots that lost red signals) were counted, and the
number of complexes that contained CA (coated) was compared to the number of complexes
that lost CA staining (uncoated). This methodology revealed a relationship between replicative
capability and uncoating kinetics of HIV-1 CA mutant viruses [2,4] along with a relationship
between reverse transcription and uncoating of HIV-1 [6].
HIV-1 infects humans but not Old World Monkeys (OWM) such as Rhesus monkey (Rh)
and cynomolgus monkey (CM). One intracellular antiviral factor, TRIM5α (tripartite motif
protein 5α), was identified by the screening of an Rh-cDNA library [7]. Members of the TRIM
protein family share RING, B-box, and coiled-coil domains; the alpha isoform of TRIM5 additionally includes a C-terminal PRYSPRY (B30.2) domain [8,9]. Though the in vivo activity of
TRIM5α has not been investigated in detail, this isoform has been shown to recognize the CA
conical core of invading viruses via the species-specific B30.2 domain [10–12]. Restriction ability of TRIM5α homologs varies among species of OWMs. Rh and CM TRIM5α homologs restrict HIV-1 but not Simian Immunodeficiency Virus isolated from macaque (SIVmac) [7,10],
whereas African green monkey (AGM) TRIM5α restricts both HIV-1 and SIVmac [10,13]. In
contrast, human (Hu) TRIM5α only weakly restricts HIV-1, but the Hu homolog potently restricts N-tropic murine leukemia virus (N-MLV) [13,14]. Interestingly, mutations in CA differentially affect viral sensitivity to TRIM5α from several species. Rh and Hu TRIM5α homologs
reportedly facilitate the destruction of the HIV-1 and N-MLV cores, respectively [15,16].
In the case of HIV type 2 (HIV-2), we previously reported that amino acid residue 120 of
the CA encoded by the GH123 strain of HIV-2 determines viral sensitivity to CM TRIM5α
[17,18]. The original GH123 strain encodes a proline residue at the 120th position of CA, and
the replication of GH123 is potently suppressed in the presence of CM TRIM5α. In contrast,
mutant GH123 viruses encoding an alanine or glutamine at the 120th position can grow efficiently in the presence of CM TRIM5α [17]. (Note that amino acid 120 in GH123 corresponds
to position 119 in other strains of HIV-2.) Furthermore, a community-based cohort study (performed in Caio, Guinea-Bissau, in west Africa) revealed that CA contains 3 proline residues, at
positions 119, 159, and 178 (residues 120, 160, and 179 in strain GH123), that were significantly associated with reduced loads of plasma HIV-2 [19]. The proline residues at these three positions also conferred slightly increased sensitivity to Hu TRIM5α [19].
In the present study, we adapted the in situ uncoating assay to HIV-2, and compared
uncoating rates of HIV-1 strain NL4-3, HIV-2 strain GH123, and mutant HIV-2 carrying non-
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proline residues at positions 120, 160, and 179 in the presence and absence of AGM, Rh, CM,
and Hu TRIM5α homologs.

Materials and Methods
Vector construction
Fragments encoding CM, Rh, AGM, and Hu TRIM5αs C-terminally tagged with hemagglutinin (HA) were amplified by PCR using the oligonucleotide primers 5’-GGCAGCTGGCCAC
CATGGCTTCTGG-3’ and 5’- CCGCGGCCGCTCAAGCAGCATAATCAG-3’ from the
cDNA clones described previously [10,20]. These DNA fragments were cloned separately into
the PvuII/NotI-sites of the pCEP4 vector (Invitrogen), which carries the hygromycin B resistance gene. GH123-Nh is a mutant of the GH123 proviral clone in which an NheI restriction
enzyme cleavage site at position 6183 was blunted and re-ligated, introducing frame-shift mutations in the env gene. ASA-Nh is a mutant of GH123-Nh in which the CA-encoding gene has
been mutated to encode a capsid protein with substitutions of alanine, serine, and alanine for
the proline residues at positions 120, 160, and 179, respectively. The HIV-2 GH123 ASA CAencoding fragment derived from ASA-Nh [19] was inserted into the PmlI/Bsu36I-sites of the
green fluorescent protein (GFP)-encoding HIV-2 construct GH123-GFP, which was a pRODenv(-)-GFP derivative carrying the gene encoding GH123 CA [18].

Cell culture, DNA transfection, and establishment of stably transfected
cell lines
Human embryonic kidney (HEK) 293T cells (ATCC CRL-11268) and HeLa cells (ATCC CCL2) were maintained at 37°C in a 5% CO2 incubator in Dulbecco’s Modified Eagle Medium
(DMEM; Nacalai Tesque, Kyoto, Japan) supplemented with 10% (v/v) heat-inactivated fetal
bovine serum (FBS; Sanko Junyaku Co., Ltd., Tokyo, Japan), and penicillin/streptomycin
(GIBCO, Auckland, NZ). HeLa cells were transfected with pCEP4 encoding HA-tagged
TRIM5α from each of the species or pCEP4 empty vector (Vc) by using the Lipofectamine
LTX reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s recommendations.
For the establishment of stably transfected cell lines, transfected cells were selected at 500 μg/ml
hygromycin B (Invitrogen), and surviving cells were propagated in the presence of hygromycin B.

Detection of HA-tagged TRIM5α in stably transfected cell lines
Expression of HA-tagged TRIM5α protein in the stably transfected cell lines was confirmed by
immunoblot analyses of the cell lysates and by immunofluorescence staining of the cells. For
immunoblotting, cells were lysed in sodium lauryl sulfate (SDS) sample buffer (100 mM sodium phosphate, pH 7.2, 1% SDS, 10% glycerol, 100 mM dithiothreitol, and 0.001% bromophenol blue). The lysates were heat-denatured and loaded onto a 4–12% gradient SDSpolyacrylamide gel (Invitrogen), and separated proteins were electronically transferred to a
polyvinylidene difluoride membrane. Following blocking (1 hr at room temperature in phosphate-buffered serine (PBS) + 0.05% (v/v) Tween 20 (PBST) containing 5% skim milk), membranes were incubated (2 hr at room temperature) with rat anti-HA monoclonal antibody
(Roche, Indianapolis, IN) or rabbit anti-actin polyclonal antibody (Sigma-Aldrich, St. Louis,
MO) diluted in PBST containing 3% skim milk. The membranes were washed with PBST and
incubated with horse radish peroxidase (HRP)-conjugated goat anti-rat IgG (for anti-HA;
American Qualex, San Clemente, CA) or protein G (for anti-actin; Sigma-Aldrich) diluted in
PBST containing 3% skim milk. After washing with PBST, bound antibodies were visualized
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with the ChemiLumi-One L chemiluminescent kit (Nacalai Tesque, Kyoto, Japan). Gel images
were captured with Ez-Capture (ATTO, Tokyo, Japan). For immunofluorescence staining,
2 × 105 HeLa cells harboring CM TRIM5α-encoding plasmid (or Vc) were fixed with 3.7%
formaldehyde/PBS for 15 min and then incubated with 0.2% Triton X-100 for 7 min. HAtagged TRIM5α was detected by incubation with anti-HA antibody diluted in PBS containing
3% skim milk for 2 hr. Cells then were rinsed with PBS, and incubated with FITC-conjugated
goat anti-rat IgG (for anti-HA, American Qualex, San Clemente, CA) diluted in PBS containing 3% skim milk. After staining of nuclei with Hoechst 33342 (Dojindo Laboratories, Kumamoto, Japan), cells were observed by fluorescence microscopy using an Eclipse TE2000-E
microscope (Nikon Corporation, Tokyo, Japan).

Virus propagation
Infectious viruses encoding GFP were prepared by transfection (using polyethyleneimine; PEI)
of HEK293T cells with proviral DNA clones (HIV-1-based MsMnG [21], HIV-2-based
GH123-GFP, or ASA-GFP) together with the pMD2G plasmid encoding vesicular stomatitis
virus envelope protein (VSV-G). VSV-G-pseudotyped HIV-1 and HIV-2 viruses for quantitative
PCR (qPCR) analyses were prepared by PEI-mediated co-transfection of HEK293T cells with
env-deficient NL-Nh, GH123-Nh, or ASA-Nh together with pMD2G. The resulting viruses
were treated with DNase I before use in HeLa cell infection. Production of fluorescence-labeled
viruses for the in situ uncoating assay was described previously [2,4,5]. Briefly, labeled HIV-2
was generated by co-transfection into HEK293T cells with env-deficient GH123-Nh or ASA-Nh,
S15-dTomato, VSV-G, and GFP-Vpx (a fusion protein of GFP and Vpx derived from SIV PBj14
[GenBank accession number: M31325]). Viral titers were determined by measuring the concentration of HIV CA protein using the RETROtek antigen ELISA kit (ZeptoMetrix, Buffalo, NY).

Viral infection assay
HeLa cells (5 x 105) transfected with HA-tagged TRIM5α-encoding vector (or with Vc alone)
were infected with viral titers of the HIV-GFP derivative equivalent to 40 ng CA. After 24 hr infection, cells were trypsinized and fixed with 3.7% formaldehyde/PBS. After changing the buffer to PBS, GFP-expressing cells were counted by flow cytometry (Becton, Dickinson and
Company, Franklin Lakes, NJ).

Quantitation of HIV DNA genomes in TRIM5α-expressing cells
HeLa cells (2 × 105/well) transfected with vector encoding TRIM5α from each of several species
(or with Vc alone) were seeded in 24-well plates on the day before the experiment. Cells were
spinoculated with viral titers of VSV-G-pseudotyped HIV-1 and HIV-2 equivalent to 200 ng
CA for 2 hr at 16°C. Cells were washed with PBS and incubated in fresh medium for 1 or 3 hr
at 37°C in a 5% CO2 incubator. After treatment of cells with RNase A, DNA was extracted
from infected cells using a GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich). Approximately 100 ng of purified DNA was used in qPCR with the KOD SYBR qPCR
Mix (TOYOBO) according to the manufacturer's protocol using a 7500 Fast Real-Time PCR
System (Applied Biosystems, Foster City, CA). PCR conditions were as follows. After initial incubations at 98°C for 2 min, 40 cycles of amplification were carried out for 10 sec at 98°C and
10 sec at 60°C (primer set: HIV-1 GAG, HIV-2 GAG and human GAPDH), 56°C (HIV-1
2-LTR) or 62°C (HIV-2 2-LTR) followed by 1 min at 68°C. Following amplification, the melting curves were determined on the SYBR channel. Primer sequences were as follows: HIV-1
GAG primers, 5’-GCAGCCATGCAAATGTTAAAAGAG-3’ (forward) and 5’-TCCCC
TTGGTTCTCTCATCTGG-3’ (reverse) [22,23], HIV-1 2-LTR primers, 5’-GTGCCC
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GTCTGTTGTGTGACT-3’ (forward) and 5’-CTTGTCTTCTTTGGGAGTGAAT
TAGC-3’ (reverse) [22,23], HIV-2 GAG primers, 5’-AGGCCACAAAATCCCGTGCCG-3’
(forward) and 5’-ACGGGGAAGTTGCGGGGCTT-3’ (reverse), HIV-2 2-LTR primers, 5’TGTTCCCTGCTAGACTCTCACCAGTGC-3’ (forward) and 5’-CCTGGCCCATGAGTA
TAATTCTGCCAATCTGG-3’ (reverse), and human GAPDH primers (for use as an internal
control), 5’-GAGCTCAACGGGAAGCTCACT-3’ (forward) and 5’-GTCAAAGGTGGAG
GAGTGGG-3’ (reverse). Genomic copy numbers were determined from threshold cycle values
following qPCR by using the standard curve of each gene copy, and then expressed as copies
per μg total DNA using the copy numbers of the internal control DNA, the human GAPDHencoding gene, in the HeLa genomic sample. For the standard curve of HIV-2 2-LTR circles,
the HIV-2 2-LTR circle junction was cloned into a TA cloning vector by PCR amplification
from the 2-LTR circles, using total DNA extracted from HeLa cells infected with VSV-pseudotyped HIV-2 GH123-Nh as the template for the reaction. In this method, levels of qPCR signals
were well correlated with DNA copy numbers between 10 and 107 copies (r2 = 0.985, HIV-1
GAG; r2 = 0.992, HIV-1 2-LTR; r2 = 0.995, HIV-2 GAG; and r2 = 0.987, HIV-2 2-LTR).

In situ uncoating assay
The in situ uncoating assay was conducted as previously described [2,4,5]. Briefly, 2.2 × 105
HeLa cells were infected with VSV-G-pseudotyped and fluorescently labeled HIV-1 or HIV-2
at viral titers equivalent to 100 ng of CA (p24 and p26, respectively). Specifically, HIV particles
contained S15-dTomato and GFP-Vpr (HIV-1) or GFP-Vpx (HIV-2). In the present study, we
used dTomato as a RFP. HeLa cells in 24-well plates were spinoculated with the labeled virus
for 2 hr at 16°C in the presence or absence of bafilomycin A (BafA) (Sigma-Aldrich). Viruscontaining supernatant then was removed and replaced with prewarmed medium in the presence or absence of BafA, incubated at 37°C for the indicated time interval, and then fixed with
3.7% formaldehyde (Polysciences, Warrington, PA) in 0.1 M PIPES buffer (pH 6.8). The fixed
HeLa cells were permeabilized with blocking solution (PBS, 10% normal donkey serum [Jackson ImmunoResearch Laboratories, West Grove, PA], 0.01% Triton X-100, 0.01% NaN3) for
5 min at room temperature; subjected to primary staining for viral CA with anti-p24 mAb
AG3.0 for HIV-1 (NIH AIDS Research and Reference Reagent Program) or anti-HIV-2 p26
(ImmunoDX, LLC, Woburn, MA) in blocking solution without Triton X-100 for 1 hr at room
temperature; and subjected to secondary staining with Cy5-labeled donkey anti-mouse antibodies (Jackson ImmuoResearch Laboratories) for 30 min at room temperature. Images were
collected and deconvolved with an Eclipse TE2000-E inverted microscope and NIS-Elements
AR software (Nikon). Following deconvolution, viral GFP punctae were semi-automatically
identified by individual GFP-intensity areas in the image picture, and Cy5- and dTomato-positive or -negative status was determined by each signal in the extractive GFP-area by using the
NIS-Elements program.

Statistical analysis
Differences in uncoating kinetics and GFP-positive area sizes were evaluated with unpaired t
tests and Mann–Whitney U test, respectively.
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Results
Establishment of HeLa cell lines stably expressing HA-tagged CM
TRIM5α
To analyze uncoating kinetics of HIV-1 and HIV-2 in the presence of OWM TRIM5α, we established HeLa cell lines stably expressing CM TRIM5α tagged with an HA epitope. HeLa cells
were transfected with a HA-tagged CM TRIM5α-encoding construct based on the pCEP4 plasmid, a backbone vector that is known to provide constitutive protein expression in almost all
mammalian cells. Transfected cells then were selected in culture medium containing hygromycin B. We established three independent cell lines stably expressing CM TRIM5α, along with
control lines that harbored the empty vector (Vc). Fig. 1A shows results of immunoblot analysis of each cell line lysate using HA-specific antibody. HA-tagged CM TRIM5α proteins were
readily detected at almost equal levels in the three HeLa cell lines transfected with the
pCEP4-CM-TRIM5α-HA construct. Furthermore, the use of anti-HA antibody followed by
FITC-labeled secondary antibody confirmed the presence of CM TRIM5α protein in virtually
all transfectants (Fig. 1B, lower panels); green fluorescence was barely detectable in Vc transfectants (Fig. 1B, upper panel). In order to determine the restriction activity against HIV-1 and
HIV-2 in these cell lines, we performed a single-round infection assay, in which viral infection
was detected as fluorescence generated by production of the GFP encoded by the viral RNA
(Fig. 1C). VSV-G-pseudotyped HIV-1 (MsMnG[21]) or HIV-2 (GH123-GFP [18]) viruses
were inoculated into the HeLa cell lines expressing CM TRIM5α and into those transfected

Fig 1. Establishment of HeLa cell lines stably expressing HA-tagged TRIM5α. HeLa cell lines were stably transfected with a vector control (Vc) or with a
vector encoding HA-tagged cynomolgus monkey (CM) TRIM5α. (A) Cells from three independent cell lines were lysed and separated on a 4–12% gradient
SDS-PAGE; intracellular HA-tagged proteins were visualized by immunoblotting using anti-HA antibody (upper panel) or anti-actin antibody (loading control;
lower panel). (B) Three independent HeLa cell lines expressing HA-tagged CM TRIM5α were stained with anti-HA primary antibody and FITC-conjugated
secondary antibody. Fluorescent signals (green) were observed by fluorescence microscopy (magnification power of 200). Nuclei (blue) were visualized by
staining with Hoechst 33342. (C) HeLa cells transfected with Vc or with vector encoding HA-tagged CM TRIM5α were infected with GFP-encoding HIV-1
(MsMnG) or HIV-2 (GH123-GFP). At 24 hr after infection, cells were collected, fixed with 3.7% formaldehyde in phosphate-buffered saline, and sorted by flow
cytometry (to detect GFP expression). Data are shown as means + SDs of three independent cell lines.
doi:10.1371/journal.pone.0121199.g001
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with Vc; at 24 hr after infection, cells were collected and fixed with formaldehyde. GFP-expressing cells were counted by flow cytometry; percentages of GFP-positive cells are shown in
Fig. 1C. In the presence of CM TRIM5α, the numbers of GFP-positive cells were reduced to
17% (HIV-1) and 21% (HIV-2) of those in the control Vc cell lines. These results confirmed
that HA-tagged CM TRIM5α retained anti-HIV activity when expressed in HeLa cells.

Adaptation of in situ uncoating assay to HIV-2 and establishment of
semi-automated fluorescent particle counting system
In the original in situ uncoating assay [2,4,5], HIV-1 was labeled with GFP-Vpr and S15-dTomato, and pseudotyped with VSV-G. Infection with labeled HIV-1 was synchronized by spinoculation. The S15-dTomato signal was expected to disappear after productive fusion of the
virion with cellular endosomal membranes. At various times after infection, the cells were fixed
and stained with an antibody against HIV-1 p24 CA. The cells then were analyzed by using
fluorescence microscopy. The total complexes that entered the cytoplasm (green spots that lost
S15-dTomato) were counted, and the number of complexes that contained CA (coated) was
compared to the number of complexes that lost CA staining (uncoated). In order to adapt this
in situ uncoating assay to HIV-2, we replaced GFP-Vpr with GFP-Vpx derived from SIV
PBj14. We used replication-incompetent HIV-2 proviral clones carrying a frame-shift mutation in the env gene, since viruses had to be pseudotyped with VSV-G to permit entry into
HeLa cells lacking the main HIV receptor CD4. Instead of the antibody against HIV-1 p24 CA,
we used anti-HIV-2 p26 antibody to detect CA. Fig. 2A shows representative images of the in
situ uncoating assay of HIV-2 in empty vector-transfected HeLa cells. The upper left, upper
middle, and lower middle panels show fluorescence for GFP-Vpx (green), S15-dTomato (red),
and HIV-2 p26 CA (blue), respectively, and the upper right panel shows a merged image for all
three colors (Fig. 2A). Thin arrows indicate GFP-positive, S15-positive, CA-positive complexes
(red, green, and blue) corresponding to intact virions. Thick arrows indicate GFP-positive,
S15-negative, CA-positive complexes (green and blue) corresponding to virions that have productively entered cells but still remain coated. Arrowheads indicate GFP-positive, S15-negative,
CA-negative complexes (green) corresponding to uncoated virions. In this representative
image, we detected one intact virion, four virions that had productively entered cells but remained coated, and nine uncoated virions (Fig. 2A). S1 Fig. shows merged images with lower
magnification, including the images shown in Fig. 2.
To facilitate counting of viral particles, and also to ensure more objective particle counting,
we established a semi-automatic counting system in the in situ uncoating assay by using the
NIS-element program. This system allowed us to count all GFP-positive particles above a certain threshold. In this system, GFP-positive viral particle images were converted to binary images and areas with fluorescent intensities above the background were determined for each
experiment. Areas with positive signals sized between 0.07 and 2.0 μm2 then were selected automatically in the image (Fig. 2A, lower left panel). Locations of these areas were pasted on
both original dTomato- and Cy5-visualized images. A merged image of the GFP binary image
with S15- and CA- images is shown in the lower right panel of Fig. 2A. Fluorescent intensities
per area were calculated automatically by the NIS-system, and the fluorescence-positive or
-negative status was determined depending on the particle’s florescent intensity. In our previous report, we counted the number of particles in a subsection of the area of the images we obtained. This process was quite laborious, and there was no guarantee that the particles that
were counted shared the same properties in all images. In this new semi-automatic counting
system, however, we were able to take all GFP-positive particles in the obtained images into
consideration. To confirm the equivalence of the new semi-automatic counting system and the
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Fig 2. HIV-2 uncoating images. (A) Images of empty vector-transfected HeLa cells infected with
fluorescently labeled HIV-2. The infected cells were fixed at 1 hr after infection. HIV-2 capsids (CA) in cells
were probed with Cy5 using anti-HIV-2 p26 antibodies. Fluorescent images of GFP-Vpx (Vpx, green),
S15-Tomato (S15, red), HIV-2 p26 (p26, blue), a merged image of these three colors (Merge), a binary image
of GFP-Vpx (Bi, green), and a merged image of Bi, S15, and p26 (Bi+S15+p26) are shown. In this image, we
detected one particle with red, green, and blue three-fluorescent co-localization (thin arrow); 4 particles with
green and blue two-fluorescent co-localization (one of them is indicated by a thick arrow); and nine particles
with green fluorescent only (one of them is indicated by an arrow head). A bar shows 10 μm. (B) Images of
HeLa cells stably expressing cynomolgus monkey TRIM5α following infection with fluorescently labeled HIV2. Layout of the images is as described in the legend for panel A. In this image, we detected no particles with
red, green, and blue co-localized fluorescence; two particles with green and blue co-localized fluorescence;
and 13 particles with green fluorescence only.
doi:10.1371/journal.pone.0121199.g002

previous manual method, we compared the results obtained by both methods (Table A in S1
File). This time, we manually counted all GFP-positive particles in the images. The correlation
coefficients (r2) were always over 0.98 when comparing between the direct manual counting
and the semi-automatic system in terms of total GFP-positive particles (GFP-positive, S15-positive, and CA-positive particles (red, green, and blue; RGB); GFP-positive, S15-negative, and
CA-positive particles (GB); and GFP-positive, S15-negative, and CA-negative particles (G)),
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Fig 3. Uncoating kinetics of HIV-1 and HIV-2 cores in TRIM5α expressing HeLa cells. In situ uncoating assay was performed in HeLa cells stably
transfected with vector encoding HA-tagged cynomolgus monkey (CM) TRIM5α (TRIM5α; closed circles) or empty vector (Vc; opened circles). Cells were
spinoculated with VSV-G-pseudotyped and GFP-Vpr/S15-dTomato-containing HIV-1 (NL-Nh/GFP-Vpr), or with VSV-G-pseudotyped GFP-Vpx/
S15-dTomato-containing HIV-2 (GH123-Nh/GFP-Vpx or ASA-Nh/GFP-Vpx), and fixed at 0, 1, 2, or 4 hr after infection. CAs of the infected viruses were
labeled by Cy5-conjugated viral-specific anti-CA antibodies, and the GFP punctae then were quantified and individually examined for the presence of
dTomato (S15) and Cy-5 (CA) signals. The percentage of the number of productively entered (S15-negative) virions that stained for p24 or p26 CA among
total number of productively entered virions (GFP-positive, S15-negative, and CA-positive particles/(GFP-positive, S15-negative, and CA-positive particles +
GFP-positive, S15-negative, and CA-negative particles)) over time following fusion is shown in the Y-axis. The 0-hr time point and bafilomycin A-treated Vctransfected cells (Vc+Baf; open squares) represent the total number of GFP-positive particles (both S15-positive and S15-negative) that stained positive for
CA among total number of GFP-positive particles. The results shown are means and SDs of three independent cell lines at each time point. *, p value less
than 0.02 when compared with values from Vc-transfected cells.
doi:10.1371/journal.pone.0121199.g003

GFP-positive viral particles that had productively entered the cytoplasm (GB and G), and CApositive particles that had productively entered the cytoplasm (GB). Percentages of coated
virus particles in productively entered particles (GB/ (GB+G) (%)) also showed good correlation (r2 = 0.987). It should be noted here, however, that semi-automatic counting always
missed some particle counts (average: 17.8% reduction) compared to direct manual counting.
This discrepancy seemed to be due to the stringent automatic counting parameters; this restriction was implemented to preclude inclusion of particles with low-level signals or of those with
large areas, which most likely corresponded to pairs of overlapping particles.

Uncoating kinetics of HIV-1 and HIV-2 in CM TRIM5α-expressing HeLa
cells
Env-deficient HIV-1 NL4-3, NL-Nh, was labeled with GFP-Vpr and S15-dTomato. Bafilomycin A (BafA), which blocks fusion of these viral and cellular membranes, was used in the negative control. This control was used to confirm that unfused viral particles failed to undergo
uncoating. Infected cells were fixed and stained with the antibody against p24 CA. The data
were graphed at each time point as a percentage of productively entered and CA-positive (coated) particles among total productively entered particles ((GB/ (GB+G) (%), Fig. 3).
In Vc-transfected cells, 54.4, 35.8, and 22.2% of productively entered HIV-1 particles were
CA-positive at 1, 2, and 4 hr, respectively, after spinoculation (Fig. 3, left graph). This progression is in good agreement with our previous report, in which we had used unmodified wildtype HeLa cells [4]. In the presence of CM TRIM5α, however, HIV-1 infection yielded apparently smaller percentages of CA-positive particles, since 32.2, 23.7, and 13.1% of productively
entered HIV-1 particles were CA-positive at 1, 2, and 4 hr, respectively, after spinoculation
(Fig. 3, left graph). However, the difference was statistically significant only at 1 hr after
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spinoculation (p <0.005); differences fell short of significance at 2 and 4 hr (p = 0.15 and
p = 0.053, respectively). On the other hand, at 0 hr (i.e., immediately after spinoculation), there
was no difference in the percentage of CA-positive particles regardless of the presence or absence of CM TRIM5α. These results indicated that CM TRIM5α hastened the HIV-1 CA
uncoating rate in HeLa cells. These observations are in good agreement with the results of previous studies, in which CA uncoating was biochemically analyzed in lysates of infected cells
[15].
We repeated our assay using HIV-2 strain GH123 and its variant ASA, which is resistant to
human [19] and CM TRIM5α (see Fig. 4B). These HIV-2 particles were labeled with GFP-Vpx
and S15-dTomato. CA-positive particles of GH123 constituted approximately 32% of productively fused virions at 1 hr after spinoculation in Vc-transfected cells, and the percentage of
CA-positive particles did not appear to change with increased time, since 28.7 and 31.3% of
productively fused virions were CA-positive at 2 and 4 hr after spinoculation (Fig. 3, middle
graph). As with HIV-1, numbers of CA-positive particles decreased more rapidly in CM
TRIM5α-expressing cells than in Vc-transfected cells. At 1, 2, and 4 hr after spinoculation, percentages of CA-positive particles were 16.6, 14.5, and 12.2%, respectively, in CM TRIM5α-expressing cells (Fig. 3, middle graph). Differences between presence and absence of CM
TRIM5α were statistically significant at 1 and 4 hr after spinoculation (p = 0.014, and
p = 0.008, respectively), but fell short of significance at 2 hr (p = 0.053). The sample images in
Fig. 2 show the same trend, since four out of 13 particles were still coated in Vc-transfected
cells (Fig. 2A), while only two out of 15 particles were coated in CM TRIM5α-expressing cells
at 1 hr after spinoculation (Fig. 2B). The difference was evident even at 0.5 hr after spinoculation (S2 Fig., left graph). When we used CM TRIM5α-resistant HIV-2 variant ASA, percentages of CA-positive particles were 20.6% in Vc cells and 23.3% in CM TRIM5α-expressing cells
at 1 hr after spinoculation, and there was no difference in percentages of CA-positive particles
at 2 and 4 hr after spinoculation when comparing Vc cells to CM TRIM5α-expressing cells
(Fig. 3, right graph). Similarly, the difference was not observed at 0.5 hr after spinoculation (S2
Fig., right graph). These results indicated that CM TRIM5α promoted accelerated uncoating of
CM TRIM5α-sensitive HIV-2 strain GH123, but failed to affect the uncoating kinetics of CM
TRIM5α-resistant HIV-2 variant ASA. These results are in good agreement with previous studies on HIV-1 [4], but represent the first demonstration that TRIM5α-sensitive HIV-2 uncoating also was accelerated in the presence of the respective TRIM5α.
In addition, we analyzed GFP-positive area sizes in all of the images we obtained and calculated the median and the interquartile range (IQR) of the area sizes (Table B in S1 File). The
areas of GFP-positive particles at 0 hr were consistently larger than those at other time points
in HIV-1-, HIV-2 GH123-, and HIV-2 ASA-infected cells (Table B in S1 File) The difference
in area likely was due to the presence or absence of envelope around the core, because almost
all the GFP-positive particles at 0 hr retained their envelope (S15-positive) just after adhesion
to the host cell membrane, while more than 56% of GFP-positive particles had already lost
their envelopes at 1 hr after spinoculation. Thus, this result suggests that GFP-Vpr and
GFP-Vpx existed not only within the HIV core but also outside of the HIV core. When HIV
invaded the host cell (by membrane fusion between the viral envelope and the cellular membrane), GFP-Vpr and GFP-Vpx outside of the core presumably were released into the cytoplasm before the core was uncoated. On the other hand, there was no difference in area sizes of
GFP-positive particles between CA-positive and CA-negative particles (data not shown), suggesting that GFP-Vpr and GFP-Vpx form some sort of complex, presumably with other viral
components, inside of the core.
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Fig 4. HeLa cell lines stably transfected with empty vector control (Vc) or with vector encoding HAtagged TRIM5α homologs from African green monkey (AGM), rhesus macaque (Rh), cynomolgus
monkey (CM), or human (Hu). (A) Three independent cell lines were tested for TRIM5α from each species
(or empty vector, Vc). Lysates from each line were separated on a 4–20% gradient gel, transferred to a
membrane, and probed with an anti-HA antibody (for HA-tagged proteins; upper panel) or anti-actin antibody
(loading control; lower panel). (B) HeLa cells stably transfected with Vc or TRIM5α-encoding vectors were
infected with GFP-encoding HIV-1 (MsMnG) or HIV-2 (GH123-GFP and ASA-GFP). GFP-positive cells
were analyzed by flow cytometry as described above. Percentages of GFP-positive cells are shown as the
means + SDs of the three independent cell lines.
doi:10.1371/journal.pone.0121199.g004

Restriction abilities of human and primate TRIM5αs against HIV-1 and
HIV-2
To compare the effects on HIV-1 and HIV-2 uncoating of TRIM5α homologs from various
primate species, we established new HeLa transfectants expressing AGM, CM, Rh, or Hu TRIM5αs as described above. Three independent cells lines were established for the TRIM5α derived from each species, and the expression of each TRIM5α protein was evaluated by
immunoblotting (Fig. 4A). Each transfectant produced a TRIM5α protein of the expected size.
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However, compared with the OWM TRIM5αs, lower amounts of the Hu TRIM5α protein
were detected in the corresponding cell lines. Therefore, we analyzed TRIM5α mRNA in these
cell lines by semi-quantitative RT-PCR and found that all transfectants expressed TRIM5α-encoding mRNAs to similar levels (data not shown). These results are in a good agreement with a
previous study showing that Hu TRIM5α accumulated to lower levels than Rh TRIM5α in
transfected cells [24].
To determine the restriction activity against HIV-1 and HIV-2 in these established cell
lines, we performed (as shown in Fig. 4B) a single-round infection assay similar to that of
Fig. 1C. VSV-G-pseudotyped MsMnG, GH-123-GFP, or ASA-GFP viruses were inoculated
into the Vc and TRIM5α-expressing transfectants; 24 hr after infection, cells were collected
and fixed with formaldehyde, and GFP-expressing cell were counted by flow cytometry. In this
experiment, approximately 15% of HeLa cells transfected with Vc were GFP-positive after infection with HIV-1, HIV-2 GH123, or HIV-2 ASA. Cells expressing AGM TRIM5α showed a
strong restriction activity against all three viruses tested, with numbers of infected (GFP-positive) cells reduced to 1%, 2.2%, and 1.8% (respectively). Cells expressing CM or Rh TRIM5α
homologs restricted HIV-1 and HIV-2 (GH123-GFP) similarly, with numbers of infected cells
reduced to <2.5%. However, the CM-TRIM5α expressing cells were more permissive for
ASA-GFP than were Rh TRIM5α expressing cells, with the CM cell line yielding 8.2% infected
cells. On the other hand, cells expressing Hu TRIM5α showed the weakest restriction activity
against HIV-1 and HIV-2 among TRIM5α-expressing lines, with the frequency of GFP-positive cells exceeding 12.3%. Notably, Hu TRIM5α-expressing cells showed no restriction activity
against ASA-GFP. These results are in good agreement with our previous reports [18,19].
We then measured RT production of VSV-G-pseudotyped NL-Nh, GH123-Nh, and
ASA-Nh in HeLa transfectants expressing Hu or OWM TRIM5α. At 1 and 3 hr after spinoculation of HeLa cells, qPCR was used to quantify the late RT products (GAG DNA) and the formation of 2-LTR circles (a surrogate for nuclear transportation) (Fig. 5). Both late RT product
synthesis and nuclear entry were decreased in TRIM5α-expressing HeLa cells. However, Hu
TRIM5α-expressing HeLa cells showed weaker restriction compared to cells expressing OWM
TRIM5αs. In the case of VSV-G pseudotyped ASA-Nh, there was no significant difference in
late RT and 2-LTR product levels among HeLa cells expressing CM or Hu TRIM5α and those
transfected with Vc. These results confirmed and extended the previous notion that OWM
TRIM5αs restrict TRIM5α-sensitive lentiviruses at an early stage of infection.

Uncoating rate of HIV-1 and HIV-2 in OWM and Hu TRIM5α-expressing
HeLa cells
To examine the uncoating rate of HIV-1 and HIV-2 in the presence of TRIM5α from different
primate species, we measured percentages of CA-positive GFP particles at 1 hr after spinoculation in CM, Rh, AGM, or Hu TRIM5α-expressing HeLa cells. Percentages of CA-positive GFP
particles in cells that had been transfected with Vc-in the presence of BafA served as a negative
control for this uncoating assay (Fig. 6). In this experiment, the frequency of CA-positive GFP
particles in GFP particles lacking S15 was 36% (NL-Nh), 24% (GH-123-Nh), or 31%
(ASA-Nh) upon infection of Vc-transfected cells. In AGM and Rh TRIM5α-expressing cells,
the corresponding frequencies were significantly decreased, with values falling to 22.3%
(p = 0.011) with NL-Nh, 12.3% (p = 0.036) with GH123-Nh, and 19.5% (p = 0.008) with
ASA-Nh upon infection of AGM TRIM5α-expressing cells, and to 25.3% (p = 0.012), 11.6%
(p = 0.004), and 17.4% (p = 0.010) (respectively) upon infection of Rh TRIM5α-expressing
cells (P values represent comparison, for a given virus, of Vc cells to those expressing
TRIM5α). In CM TRIM5α-expressing cells, the frequencies of CA-positive GFP particles were
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Fig 5. Measurement of the reverse-transcribed products of HIV-1 and HIV-2 in the TRIM5α-expressing
HeLa cells. Whole DNA containing reverse-transcribed viral products was extracted from HeLa cell lines
expressing HA-tagged African green monkey (AGM), rhesus macaque (Rh), cynomolgus monkey (CM), or
human (Hu) TRIM5α, at 1 hr (white bars) and 3 hr (black bars) after spinoculation with VSV-G-pseudotyped
HIV-1 (NL-Nh) or HIV-2 (GH123-Nh, ASA-Nh). HeLa cell lines stably transfected with empty vector (Vc)
served as the positive controls in this assay. The extracted DNA was subjected to quantitative PCR using
GAG-specific primers (for RT products) and 2-LTR-specific primers (for nuclear-transported viral DNA).
Values were normalized to GAPDH-encoding DNA to yield viral DNA copy number per ng of total DNA.
Results shown are the means + SDs of three independent cell lines. Note that viral DNA copy number was
normalized per ng HeLa DNA (assessed as the copy number of the GAPDH-encoding gene in each sample);
because human genomic DNA is present at approximately 1.0 to 2.0 pg per cell, one nanogram of HeLa DNA
should correspond to the genomic DNA content of approximately 1,000 cells. * and **, p value less than 0.05
and 0.005, respectively, when compared with values in Vc-transfected cells at the respective time points.
doi:10.1371/journal.pone.0121199.g005
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Fig 6. Uncoating rates of HIV-1 and HIV-2 cores in HeLa cell lines stably transfected with empty vector control (Vc) or with vector encoding HAtagged TRIM5α from African green monkey (AGM), rhesus macaque (Rh), cynomolgus monkey (CM), or human (Hu). In situ uncoating assay was
performed in multiple HeLa cell lines derived from each construct. At 1 hr after spinoculation with fluorescently labeled HIV-1 (NL-Nh/GFP-Vpr) or HIV-2
(GH123-Nh/GFP-Vpx or ASA-Nh/GFP-Vpx), cells were fixed. The infecting viruses and GFP punctae were visualized and analyzed as described in the
legend for Fig. 3. Data shown in the Y-axis are percentage of the number of productively entered (S15-negative) virions that stained for p24 or p26 CA among
total number of productively entered virions (GFP-positive, S15-negative, and CA-positive particles/(GFP-positive, S15-negative, and CA-positive particles +
GFP-positive, S15-negative, and CA-negative particles)). The bafilomycin A-treated Vc cells (Vc+BAF) were used as a negative control and represent
percentage of the total number of GFP-positive particles (both S15-positive and S15-negative) that stained positive for CA among total number of GFPpositive particles. The results shown are means + SDs of three independent transfected cell lines. * and **, p value less than 0.05 and 0.005, respectively,
when compared with values in Vc-transfected cells.
doi:10.1371/journal.pone.0121199.g006

significantly decreased in NL-Nh- (26.3%, p = 0.022) and GH123-Nh-infected cells (16.7%,
p = 0.023), but not in ASA-Nh-infected cells (28.7%, p = 0.547), confirming a distinction observed above in Figs. 3 and 4B. On the other hand, in Hu TRIM5α-expressing cells, frequencies
of CA-positive GFP particles were not significantly decreased (30.5% in NL-Nh-, 27.3% in
GH123-Nh-, and 28.5% in ASA-Nh-infected cells) in comparison with those in Vc expressed
cells. These results indicated that TRIM5α-sensitive lentivirus showed accelerated uncoating in
the presence of certain TRIM5αs, while uncoating of TRIM5α-resistant lentiviruses was not affected by the respective TRIM5α.

Discussion
In the present study, we report the adaptation of an in situ uncoating assay to HIV-2 by modification of a method previously reported for HIV-1 [4,5]. We used a SIVsm-derived GFP-Vpx
fusion and a monoclonal antibody against HIV-2 CA in place of (respectively) an HIV-1-derived GFP-Vpr fusion and a monoclonal antibody against HIV-1 CA. We also showed that
both HIV-1 NL4-3 and HIV-2 GH123 exhibited accelerated uncoating in the presence of
OWM TRIM5s. Furthermore, a CM TRIM5α-resistant HIV-2 variant, GH123 ASA, did not
show accelerated uncoating in the presence of CM TRIM5α, confirming that accelerated
uncoating is associated with restriction activity of TRIM5α against HIV.
In the presence of OWM TRIM5αs, accelerated uncoating was evident at 1 hr after spinoculation (Figs. 3 and 6) and continued to be evident at 4 hr after spinoculation (Fig. 2). The kinetics of accelerated uncoating in the present study was in good agreement with that in previous
reports [4,5]. In those reports, uncoating speed was assayed by measuring the amount of CA
protein, which possesses a density equivalent to that of the assembled capsid, after sucrose density gradient centrifugation of infected cell lysates. The density method, however, cannot
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differentiate productively entered HIV particles from those that were simply endocytosed,
since whole cells were lysed and directly subjected to sucrose density gradient centrifugation.
Therefore, the in situ uncoating assay described here reveals, for the first time, that OWM TRIM5αs cause accelerated uncoating of productively entered HIV-1 and HIV-2 particles.
In the present study, we also established a semi-automatic counting system for use in the in
situ uncoating assay. This system not only allowed us to count particles in a convenient and
speedy way, but also ensured that we were counting particles in a consistent and unbiased fashion in all of the obtained images. Comparison of results obtained by the semi-automated
counting system with those obtained by the previous manual counting method showed a high
correlation coefficient, confirming the equivalence of these two methods (Table A in S1 File).
The semi-automatic counting system also allowed us to compare the sizes of fluorescent particles among images obtained in a given experiment. As shown in Table B in S1 File, GFP-labeled
particles of both HIV-1 and HIV-2 apparently became smaller after productive entry into the
host cells. Both HIV-1 Vpr and HIV-2/SIV Vpx have been shown to bind to the p6 domain of
the Pr55gag protein and are incorporated into virus particles [25–27]. Vpr in viral particles is
necessary for the efficient translocation of the PIC into the nucleus and subsequent infection in
non-dividing cells [28–30]. HIV-1 Vpr and HIV-2 Vpx have been found in the mature cores of
the respective viruses [26,31]. Therefore, it is tempting to speculate that HIV-1 Vpr and HIV-2
Vpx are packaged not only inside of, but also outside of, the virion cores; only Vpr and Vpx
packaged outside of the core would be released into the cytoplasm when HIV productively enters into host cells. Further experiments will be needed to test this hypothesis.
When we compared uncoating kinetics between HIV-1 NL4-3 and HIV-2 GH123 in the absence of OWM TRIM5α, HIV-2 GH123 tended to show faster uncoating kinetics than did
HIV-1 NL4-3: at 1 hr after spinoculation, more than 50% of HIV-1 NL4-3 particles that had
productively entered cells remained coated, while less than 35% of HIV-2 GH123 or GH123
ASA particles that had productively entered cells were coated (Fig. 3). This effect also was evident in the independent experiments shown in Fig. 6. At present, the basis for the difference in
uncoating kinetics between HIV-1 NL4-3 and HIV-2 GH123 is unclear. A difference in antiCA antibody affinity may affect the uncoating kinetics, since we used distinct monoclonal antibodies against HIV-1 and HIV-2 CA proteins. However, we do not favor this explanation,
given that the percentages of coated HIV-2 GH123 particles remained stable after 1 hr, while
those of HIV-1 NL4-3 continued to decrease until 4 hr. Alternatively, differences in the GFPlabeled virus accessory proteins (Vpr and Vpx) may affect the uncoating kinetics, although we
note that there was no difference in the sizes of GFP-positive particles between HIV-1 NL4-3
and HIV-2 GH123. Therefore, we presume that the uncoating kinetics of HIV-2 GH123 are indeed faster than that of HIV-1 NL4-3. Further studies, including in situ uncoating assays using
other HIV-1 and HIV-2 strains, are needed before we can generalize from this observation.
Fig. 4A shows that levels of human TRIM5α protein expression in established transfectants
were lower than those of OWM TRIM5αs. This result is in good agreement with our previous
report, in which human TRIM5α was expressed using an SeV vector [32]. However, levels of
the human TRIM5α-encoding RNA were similar to those of other TRIM5α-encoding transcripts when assayed by semi-quantitative RT-PCR. Human TRIM5α- and other TRIM5α-encoding genes were expressed under control of the same CMV promoter in the pCEP4-vector.
These results and those of the previous study [24] suggested that human TRIM5α protein exhibits lower stability than OWM TRIM5αs in human cells. The question of whether OWM
TRIM5αs also exhibit prolonged stability in their respective OWM cells will require further
investigation.
Very recently, it was reported that RT reactions may be dispensable for uncoating and nuclear import of the PIC [33]. Authors of that communication used an RT-deficient HIV-1
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isolate that contained fluorescently labeled APOBEC3F. However, when those authors used
RT-intact wild-type HIV-1, only *6% of fluorescent signals in the nuclei co-localized with
HIV-1 RNA signals [33]. These results, together with those of the previous study [6], indicate
that HIV core plays an important role in RT and the establishment of infection. These issues
will need to be clarified in future studies.
In conclusion, we adapted an HIV-1 in situ uncoating assay to HIV-2 and showed that both
HIV-1 and HIV-2 exhibited accelerated uncoating in the presence of OWM TRIM5αs. We anticipate that the use of this imaging technology in our virus uncoating assay will permit us to
use dyes of distinct emission wavelengths to distinguish the roles of various host factors involved in uncoating.

Supporting Information
S1 Fig. HIV-2 uncoating images at lower magnification. Fluorescently labeled HIV-2 were
spinoculated into empty vector-transfected (Vc/HeLa) or cynomolgus monkey TRIM5α-expressing (CM TRIM5α/HeLa) HeLa cells. Cells then were treated and analyzed as described in
the legend for Fig. 2. Merged images of GFP-Vpx, S15-dTomato, and HIV-2 P26 fluorescence
are shown. Bars indicate 20 μm. Dashed lines indicate the regions shown at higher magnification in Fig. 2.
(EPS)
S2 Fig. Uncoating kinetics of HIV-2 cores in TRIM5α-expressing HeLa cells in a short
time-course. In situ uncoating assay was performed in HeLa cells stably transfected with vector
encoding HA-tagged cynomolgus monkey (CM) TRIM5α (TRIM5α; closed circles) or empty
vector (Vc; opened circles). Cells were spinoculated with VSV-G-pseudotyped GFP-Vpx/
S15-dTomato-containing HIV-2 (GH123-Nh/GFP-Vpx or ASA-Nh/GFP-Vpx), and fixed at 0,
0.5, or 1 hr after infection. HIV-2 CAs were labeled after fixing the cells, and then analyzed as
described in the legend for Fig. 3. The results shown are means ± SDs of three independent cell
lines at each time point.  , p value less than 0.05 when compared with values from Vctransfected cells.
(EPS)
S1 File. Table A, Comparison between semi-automatic and manual counting. Table B, Median GFP areas.
(DOCX)
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